Loading clinical trials...
Loading clinical trials...
A Randomized, Double-masked, Placebo-controlled Study to Assess the Efficacy and Safety of REGN1908-1909 to Reduce Signs and Symptoms of Allergic Conjunctivitis in Participants With Cat Allergy
Conditions
Interventions
REGN1908
REGN1909
+1 more
Locations
4
United States
Andover Eye Associates
Andover, Massachusetts, United States
Kingston Health Sciences Centre
Kingston, Ontario, Canada
Red Maple Trials Inc.
Ottawa, Ontario, Canada
Clinique de Specialisee en Allergie de la Capitale
Québec, Canada
Start Date
November 6, 2024
Primary Completion Date
May 10, 2025
Completion Date
August 2, 2025
Last Updated
September 5, 2025
NCT06686472
NCT05839938
NCT05186025
NCT05191186
NCT06800274
NCT06459219
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions